Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., . . . Tannir, N. M. (2021). Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer.
Chicago Style CitationMotzer, Robert J., et al. "Survival Outcomes and Independent Response Assessment With Nivolumab Plus Ipilimumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma: 42-month Follow-up of a Randomized Phase 3 Clinical Trial." J Immunother Cancer 2021.
Cita MLAMotzer, Robert J., et al. "Survival Outcomes and Independent Response Assessment With Nivolumab Plus Ipilimumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma: 42-month Follow-up of a Randomized Phase 3 Clinical Trial." J Immunother Cancer 2021.